[A19-64] Nintedanib (idiopathic pulmonary fibrosis) - Addendum to Commission A19-36
Last updated 17.10.2019
Project no.:
A19-64
Commission:
Commission awarded on 26.08.2019 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Airways and respiratory system
Indication:
Adults with idiopathic pulmonary fibrosis
Result of dossier assessment:
Conclusion of dossier assessment A19-36 unchanged: proof of minor added benefit
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A19-36 | Nintedanib (idiopathic pulmonary fibrosis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2019-10-17 A G-BA decision was published.